S
Satellite Bio
Specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering
About Satellite Bio
Satellite Bio is a pioneering startup in the field of regenerative medicine, aiming to revolutionize the way we treat some of the most elusive diseases known to mankind. The company's innovative approach involves the delivery of living cells, known as Satellite Adaptive Tissues or 'Satellites', into the body to repair or even replace critical organ function.
The Satellites, depicted as round, flexible, translucent pink discs, represent a new method of assembling healthy cells for therapeutic use. This next-generation regenerative medicine has the potential to change the course of disease treatment and restore hope to many patients.
Satellite Bio operates in the healthcare market, specifically within the regenerative medicine sector. Its clients are primarily patients suffering from diseases that currently have limited treatment options. The business model revolves around the development, production, and delivery of these Satellite Adaptive Tissues.
The company generates revenue by providing these innovative therapies to patients. As a pioneer in this field, Satellite Bio has the potential to establish a strong market position, offering a unique solution to a pressing healthcare challenge.
In summary, Satellite Bio is a groundbreaking startup that leverages the power of regenerative medicine to offer new hope for patients with elusive diseases. Its innovative approach to cell therapy could redefine the healthcare landscape and establish the company as a leader in this emerging field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 76.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Tissue Engineering, Regenerative Medicine, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $110M | $440M | Polaris Partners · Waterman Ventures · Catalio Capital Management · Lightspeed | ↗ |
| SEEDOther financing | Nov 2020 | — | — | Polaris Partners · Lightspeed · aMoon Fund · Lightspeed Financial | — |
Growth signals
Latest recorded traffic for Satellite Bio is 2.1K monthly website visits, up 281.8% over the last three months. Satellite Bio's team grew 19% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Lightspeed Financial
Polaris Partners
Lightspeed
aMoon Fund
Series A3 investors entered at this stage
- WVWaterman Ventures
Catalio Capital Management
Section 32
Other known investors2 additional known investors
Boston University
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Satellite Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Satellite Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.